A Yale study published on the cover of the journal Blood explains basic scientific discoveries that could lead to innovative therapies for acute myeloid leukemia, and specifically a rare and ...
Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia ...
The results of research by scientists at Barts Cancer Institute at Queen Mary University of London has identified a sequential drug treatment approach that can reverse the resistance of leukemia cells ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Impact of an Etoposide Chemotherapy Shortage on Patients With Extensive-Stage Small-Cell Lung Cancer: Results of a Natural Experiment Historically, patients with hematologic malignancies are referred ...
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells. By ...
Cancer cells are relentless in their quest to grow and divide, often rewiring their metabolism and modifying RNA to stay one step ahead. Now, researchers at the UCLA Health Jonsson Comprehensive ...
Acute myeloid leukemia (AML) is a rare and aggressive hematologic malignancy. AML progresses rapidly and is indicated by an excess of immature white blood cells. It is caused by high mutational burden ...
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback